礼来(LLY)

搜索文档
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street
The Motley Fool· 2025-09-12 16:44
The positives for this big drugmaker appear to outweigh the negatives.For a while, it seemed that nothing could go wrong for Eli Lilly (LLY 0.23%). Surging sales for Lilly's type 2 diabetes drug Mounjaro and great expectations for its obesity drug Zepbound fueled massive gains for the pharma stock.Along the way, Lilly became the largest healthcare company on the planet based on market cap. However, the story hasn't been so great for the drugmaker since last summer. Its share price remains more than 20% belo ...
Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
CNBC· 2025-09-12 02:40
Jose Luis Pelaez Inc | Digitalvision | Getty ImagesHealth-care inflation is fueling higher coverage costs, setting the stage for what could be the largest increase in health-care spending by large employers in 15 years.Medical care costs in August rose 4.2% on an annualized basis, according to the Labor Department's Consumer Price Index, compared to an overall inflation rate of 2.9%. The cost of doctors' visits climbed 3.5%, while hospital and outpatient services jumped 5.3%.Those price increases are contri ...
Eli Lilly loses appeal of $183.7 million Medicaid fraud award
Reuters· 2025-09-12 01:30
A federal appeals court on Thursday rejected Eli Lilly's appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid. ...
Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
Prnewswire· 2025-09-11 22:00
Accessibility StatementSkip Navigation INDIANAPOLIS, Sept. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of ...
Why Eli Lilly's Stock Could Be Gearing Up for a Big Rally
Yahoo Finance· 2025-09-11 20:45
Key Points If it obtains regulatory approval for its GLP-1 pill, that would be a huge catalyst ahead. The company already has injectable GLP-1 drugs that are generating billions in revenue, Despite its valuation, the stock only appears expensive when you look at the short term. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) shares have been disappointing to own this year. As of the end of last week, they were down more than 4% since the start of the year. But this has still been a ...
Global Markets Hit Records Amid Geopolitical Tensions and Major Corporate Shifts
Stock Market News· 2025-09-11 09:08
全球股市表现 - 标普500指数创历史新高 日经平均指数达历史峰值 投资者等待美国通胀报告[2] - 韩国股市开盘受科技和电池板块上涨推动[2] 货币与债券市场 - 澳元接近十个月高位 市场等待美国CPI数据发布[3] - 美元保持稳定 市场关注通胀和央行政策[3] - 台湾隔夜银行间利率维持在0.805% 与前一交易日持平[3] - 日本5年期国债收益率上升0.5个基点至1.115%[3] 制药行业动态 - 诺和诺德宣布全球裁员9000人 约占员工总数11.5% 以应对礼来的激烈竞争[4] - 公司预计到2026年每年节省80亿丹麦克朗(约12.5亿美元) 其中5000个岗位在丹麦[4] - 软银集团股价上涨7.5%[5] 地缘政治局势 - 以色列在卡塔尔空袭哈马斯领导人 引发国际谴责并加剧地区紧张[6] - 俄罗斯谴责该行动"严重违反国际法" 新加坡外交部称其破坏加沙停火谈判[6] - 卡塔尔总理表示正在准备"区域回应" 并讨论多哈峰会[6] 乌克兰援助计划 - 欧盟向乌克兰提供10亿欧元贷款 资金来自被冻结的俄罗斯资产收益[7] - 该援助属于G7额外收入加速(ERA)计划 旨在支持乌克兰国防工业和经济稳定[7] - 波兰击落俄罗斯无人机 标志着北约成员国首次在此背景下采取战斗行动[7] 美韩外交关系 - 韩国要求美国迅速释放被拘留的韩国工人 这些工人在现代汽车和LG能源解决方案电池厂建设现场被扣押[10] - 美国国务卿表示特朗普总统已指示按照韩国意愿采取快速行动[10] 美国外交活动 - 美国国务卿马可·卢比奥与中国外长王毅讨论全球和区域问题 延续此前在马来西亚的会晤[9] 英国房地产市场 - 英国房价出现超过一年半以来最大跌幅 显示潜在经济阻力[12]
知名巨头突然宣布:裁员9000人,此前年薪5000万元CEO被炒
每日经济新闻· 2025-09-11 06:30
公司重组与裁员 - 诺和诺德宣布全球重组裁员9000人 占员工总数11.5% [1] - 裁员包括丹麦本土5000个职位 预计年节省80亿丹麦克朗(约12.6亿美元)开支 [1] - 第三季度将报告一次性90亿丹麦克朗重组成本 第四季度预计节省10亿丹麦克朗 [7] 管理层变动与股价表现 - 2024年5月更换原CEO周德赋 7月任命Maziar Mike Doustdar为新任CEO [6] - 原CEO 2023年年薪6820万丹麦克朗(约952万美元) 2024年降至5710万丹麦克朗(约797万美元) [6] - 近一年股价下跌近60% 年内跌幅超30% 市值2410亿美元较一年前蒸发超3500亿美元 [3] 财务业绩与预期 - 2025年第一季度总收入780.87亿丹麦克朗(约112.16亿美元) 同比增长18% [3] - 司美格鲁肽销售额占总营收71% [3] - 下调2024年营业利润增长率预期至4%-10% 原预测为10%-16% [7] 产品竞争格局 - 司美格鲁肽2025年Q1全球销售额超越默沙东K药 暂居全球"药王" [10] - 礼来替尔泊肽美国市场处方量占比53.3% 临床研究显示其效果优于司美格鲁肽 [10][11] - 司美格鲁肽核心专利2026年到期 中国超10家药企仿制药进入后期临床阶段 [12] 市场环境与战略 - GLP-1减肥药赛道竞争白热化 中国31款减重适应证药物进入临床阶段 [9] - 中国市场糖尿病药物销售下滑 减重药物处于放量初期 [11] - 公司强调将持续投资创新 应对仿制药上市后的竞争环境 [12] 行业发展趋势 - 中国GLP-1减肥药市场规模预计2030年超378.52亿元 [9] - 礼来2025年Q1总收入127.29亿美元(同比增45%) 替尔泊肽贡献61.5亿美元占比48% [10] - 全球GLP-1药物市场竞争激烈 消费者驱动因素日益增强 [6][11]
Oxford Industries says new Lilly Pulitzer offerings are winning over shoppers, but its Tommy Bahama line is lagging
MarketWatch· 2025-09-11 05:57
Resort-style clothing maker Oxford Industries Inc. on Wednesday offered up mixed second-quarter results and third-quarter expectations, and said that while new Lilly Pulitzer offerings were attracting shoppers, its Tommy Bahama line wasn't. ...
Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up
Fastcompany· 2025-09-11 03:51
公司战略调整 - 丹麦制药巨头诺和诺德宣布计划裁员11%以应对竞争压力 [1] - 公司旗下拥有热门减肥药物Ozempic和Wegovy产品线 [1] 行业竞争格局 - 竞争对手礼来公司持续侵蚀市场份额 [1]
The Big 3: TGT, LLY, C
Youtube· 2025-09-11 01:01
市场整体表现 - 纳斯达克和标普500指数创下历史新高 但市场内部结构表现疲弱 仅靠少数股票支撑 [1][2] - 标普100指数中超过70只成分股下跌 市场广度显著恶化 [3] - 当前市场环境适合日内反转交易策略 [3] Target公司分析 - 公司股价年内累计下跌34% 面临90美元关键支撑位考验 [4][5] - 零售行业面临严峻挑战 利润率持续承压 [5] - 技术分析显示90美元为重要关口 跌破后可能下探85美元 [5][6][8] - 股价已跌破成交量分布控制点96.66美元 且低于线性回归线85美元 [11][13] Eli Lilly公司分析 - 公司受政府限制医药广告政策影响较小 显示股价韧性 [14] - 股价从623美元上涨至750美元以上 呈现明显上升趋势 [15] - GLP1药物行业处于发展初期 具有长期增长潜力 [16] - 技术分析显示751美元为当前关键位 780美元和252日指数移动均线形成阻力 [17][18][22] Citigroup公司分析 - 公司股价年内上涨40% 表现优于同业 [24] - 金融板块上涨缺乏基本面支撑 与经济疲弱背景相悖 [24][25] - 收益率曲线平坦化和美联储降息预期可能对金融股不利 [24][26] - 技术分析显示96美元为重要阻力位 RSI指标显示动量减弱 [27][28][30] - 95-96美元区间形成关键支撑 跌破可能下探89美元 [28][29]